Results 261 to 270 of about 135,512 (307)
Some of the next articles are maybe not open access.
Nature Reviews Drug Discovery, 2017
The European Medicines Agency's PRIME scheme to accelerate the development of promising drugs that address unmet medical needs has enrolled 19 products in its first year, showing considerable overlap with FDA breakthrough therapy designees but also key differences.
openaire +2 more sources
The European Medicines Agency's PRIME scheme to accelerate the development of promising drugs that address unmet medical needs has enrolled 19 products in its first year, showing considerable overlap with FDA breakthrough therapy designees but also key differences.
openaire +2 more sources
Multiple sclerosis (MS) is a progressive autoimmune and neurodegenerative disease. One of the major symptoms of MS is fatigue which interferes individually with daily life activities and declines performance during tasks. Measuring associations between fatigue and activity performance (i.e., activity-related fatigability) in real-life situations ...
Suikkanen, Sara +6 more
openaire +1 more source
Suikkanen, Sara +6 more
openaire +1 more source
The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
Pharmaceutics, 2021M Begoña Delgado-Charro
exaly
EMA vs EMACO in the treatment of gestational trophoblastic neoplasia
Gynecologic Oncology, 2020Nida Jareemit +2 more
exaly
EMA-amplicon-based sequencing informs risk assessment analysis of water treatment systems
Science of the Total Environment, 2020Brandon Reyneke +2 more
exaly
2009
Članak donosi činjenice iz životopisa autora koje su relevantne za njegovo djelovanje i opus. Zatim slijedi reprezentativan izbor djela, a na kraju se selektivno navode bibliografija i literatura.
openaire +1 more source
Članak donosi činjenice iz životopisa autora koje su relevantne za njegovo djelovanje i opus. Zatim slijedi reprezentativan izbor djela, a na kraju se selektivno navode bibliografija i literatura.
openaire +1 more source